OBJECTIVES: Dexmedetomidine use for sedation in the pediatric intensive care units (PICUs) has increased since its initial US Food and Drug Administration (FDA) approval in adults. However, there is limited evidence to direct providers regarding current usage, dosing, and monitoring for withdrawal symptoms in pediatric patients. This study sought to determine the utilization of dexmedetomidine and management of dexmedetomidine withdrawal symptoms among PICU physicians. METHODS: A questionnaire survey was distributed to all members of the American Academy of Pediatrics Section on Critical Care. It assessed the practice site demographics, indication, dosing, and duration of dexmedetomidine infusion, unit protocol, and strategies for management of dexmedetomidine withdrawal. RESULTS: A total of 147 surveys (21.1%) were returned and analyzed. The reported uses for dexmedetomidine were as a primary sedative (59.9%), adjunctive agent for sedation (82.3%), and adjunctive agent to assist weaning sedation (62.6%) or from mechanical ventilation (70.1%). One hundred twenty-nine respondents (87.8%) had concerns over dexmedetomidine withdrawal, with 59 respondents becoming concerned after 120 hours of infusion (45.7%). Most respondents reported managing dexmedetomidine withdrawal symptoms via a regimented wean and initiation of clonidine (81%). Units with >1000 admissions per year were more likely to have a protocol related to dexmedetomidine use (p = 0.021). Units with >1000 admissions per year reported using clonidine for withdrawal at a higher rate, whereas units with ≤1000 admissions per year used a systematic wean of dexmedetomidine (p = 0.014). CONCLUSIONS: Dexmedetomidine use in the PICU is varied among pediatric intensive care physicians. Intensivists have withdrawal concerns after dexmedetomidine discontinuation, and the primary management of this withdrawal phenomenon is the initiation of clonidine with a regimented dexmedetomidine wean.
OBJECTIVES:Dexmedetomidine use for sedation in the pediatric intensive care units (PICUs) has increased since its initial US Food and Drug Administration (FDA) approval in adults. However, there is limited evidence to direct providers regarding current usage, dosing, and monitoring for withdrawal symptoms in pediatric patients. This study sought to determine the utilization of dexmedetomidine and management of dexmedetomidine withdrawal symptoms among PICU physicians. METHODS: A questionnaire survey was distributed to all members of the American Academy of Pediatrics Section on Critical Care. It assessed the practice site demographics, indication, dosing, and duration of dexmedetomidine infusion, unit protocol, and strategies for management of dexmedetomidine withdrawal. RESULTS: A total of 147 surveys (21.1%) were returned and analyzed. The reported uses for dexmedetomidine were as a primary sedative (59.9%), adjunctive agent for sedation (82.3%), and adjunctive agent to assist weaning sedation (62.6%) or from mechanical ventilation (70.1%). One hundred twenty-nine respondents (87.8%) had concerns over dexmedetomidine withdrawal, with 59 respondents becoming concerned after 120 hours of infusion (45.7%). Most respondents reported managing dexmedetomidine withdrawal symptoms via a regimented wean and initiation of clonidine (81%). Units with >1000 admissions per year were more likely to have a protocol related to dexmedetomidine use (p = 0.021). Units with >1000 admissions per year reported using clonidine for withdrawal at a higher rate, whereas units with ≤1000 admissions per year used a systematic wean of dexmedetomidine (p = 0.014). CONCLUSIONS:Dexmedetomidine use in the PICU is varied among pediatric intensive care physicians. Intensivists have withdrawal concerns after dexmedetomidine discontinuation, and the primary management of this withdrawal phenomenon is the initiation of clonidine with a regimented dexmedetomidine wean.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: James Walker; Matt Maccallum; Carl Fischer; Robert Kopcha; Roy Saylors; John McCall Journal: J Burn Care Res Date: 2006 Mar-Apr Impact factor: 1.845
Authors: Kanwaljeet J S Anand; Douglas F Willson; John Berger; Rick Harrison; Kathleen L Meert; Jerry Zimmerman; Joseph Carcillo; Christopher J L Newth; Parthak Prodhan; J Michael Dean; Carol Nicholson Journal: Pediatrics Date: 2010-04-19 Impact factor: 7.124
Authors: Thao L Nguyen; Weng Man Lam; Hillary Orr; Brian Gulbis; Riza Mauricio; Eric Tom; Vinai M Modem; Alvaro Coronado-Munoz Journal: J Pediatr Pharmacol Ther Date: 2021-11-10
Authors: Krupa Bhatt; Ashley Thompson Quan; Laura Baumgartner; Shawn Jia; Rhiannon Croci; Kathleen Puntillo; James Ramsay; Rima H Bouajram Journal: Crit Care Explor Date: 2020-11-03
Authors: Rima H Bouajram; Krupa Bhatt; Rhiannon Croci; Laura Baumgartner; Kathleen Puntillo; James Ramsay; Ashley Thompson Journal: Crit Care Explor Date: 2019-08-09
Authors: Ashley D Turner; Travis Sullivan; Kurt Drury; Trevor A Hall; Cydni N Williams; Kristin P Guilliams; Sarah Murphy; A M Iqbal O'Meara Journal: Front Behav Neurosci Date: 2021-08-16 Impact factor: 3.558